Changes in the ocular surface and meibomian glands following administration of 0.01 and 0.02% atropine
PurposeTo investigate the changes in the ocular surface and meibomian glands following the administration of 0.01 and 0.02% atropine.SettingThe Second Affiliated Hospital of Anhui Medical University, Anhui, China.MethodsIn this randomized controlled study, the 0.01% group (18 patients, 36 eyes) and...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1585396/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849706155361697792 |
|---|---|
| author | Xueyan Li Yanying Zhu Haiyan Xie Yuexin Chen Yukun Liu Xiaochen Xu Jing Wang |
| author_facet | Xueyan Li Yanying Zhu Haiyan Xie Yuexin Chen Yukun Liu Xiaochen Xu Jing Wang |
| author_sort | Xueyan Li |
| collection | DOAJ |
| description | PurposeTo investigate the changes in the ocular surface and meibomian glands following the administration of 0.01 and 0.02% atropine.SettingThe Second Affiliated Hospital of Anhui Medical University, Anhui, China.MethodsIn this randomized controlled study, the 0.01% group (18 patients, 36 eyes) and the 0.02% group (15 patients, 30 eyes) underwent assessments using the Ocular Surface Disease Index (OSDI), Visual Analogue scale (VAS), tear meniscus height (TMH), first noninvasive tear film breakup time (fNIBUT), and average noninvasive tear film breakup time (avNIBUT) at baseline (before administration) and at 1, 3, 6, and 12 months post-treatment. The meibomian glands of both the upper (U) and lower (L) eyelids were evaluated using Meibomian Gland Bio-image Analyzer, measuring parameters such as average gland diameter (avGD), average gland length (avGL), average gland area (avGA), deformation coefficient (DC), and gland visibility score (VS).ResultsThere were no statistically significant differences in any of the parameters within the 0.01% group (all p > 0.05). In the within-group comparisons of the 0.02% group, OSDI was higher at 3 month (p = 0.006) and was lower at 12 months (p = 0.038). VAS was higher at 3 months and 6 months (all p < 0.05). TMH was lower at 12 months (all p < 0.05). U-VS was lower at 3 months (p = 0.006) and higher at 6 and 12 months (all p < 0.05). L-avGL was higher at 1 month (p = 0.001) and lower at 6 months (p = 0.013). L-VS was higher at 6 and 12 months (all p < 0.05). In the 0.02% group, at 3 months, the change in U-VS and L-VS were positively correlated with the change in the VAS (r = 0.542, p = 0.037; r = 0.614, p = 0.015). At 6 months, the change in L-VS was positively correlated with the change in OSDI (r = 0.610, p = 0.016). At 12 months, the change in U-VS was positively correlated with the change in TMH (r = 0.521, p = 0.003).Conclusion0.01% atropine had no significant impact. 0.02% atropine eye drops affected the lipid secretion of meibomian glands, tear meniscus height and subjective discomfort. |
| format | Article |
| id | doaj-art-54262aa9e583435aa6e4e5873c2e12c5 |
| institution | DOAJ |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-54262aa9e583435aa6e4e5873c2e12c52025-08-20T03:16:16ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-06-011210.3389/fmed.2025.15853961585396Changes in the ocular surface and meibomian glands following administration of 0.01 and 0.02% atropineXueyan Li0Yanying Zhu1Haiyan Xie2Yuexin Chen3Yukun Liu4Xiaochen Xu5Jing Wang6The Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, ChinaThe Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, ChinaThe Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, ChinaThe Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, ChinaThe Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, ChinaWuhu City Eye Hospital, Wuhu, ChinaThe Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, ChinaPurposeTo investigate the changes in the ocular surface and meibomian glands following the administration of 0.01 and 0.02% atropine.SettingThe Second Affiliated Hospital of Anhui Medical University, Anhui, China.MethodsIn this randomized controlled study, the 0.01% group (18 patients, 36 eyes) and the 0.02% group (15 patients, 30 eyes) underwent assessments using the Ocular Surface Disease Index (OSDI), Visual Analogue scale (VAS), tear meniscus height (TMH), first noninvasive tear film breakup time (fNIBUT), and average noninvasive tear film breakup time (avNIBUT) at baseline (before administration) and at 1, 3, 6, and 12 months post-treatment. The meibomian glands of both the upper (U) and lower (L) eyelids were evaluated using Meibomian Gland Bio-image Analyzer, measuring parameters such as average gland diameter (avGD), average gland length (avGL), average gland area (avGA), deformation coefficient (DC), and gland visibility score (VS).ResultsThere were no statistically significant differences in any of the parameters within the 0.01% group (all p > 0.05). In the within-group comparisons of the 0.02% group, OSDI was higher at 3 month (p = 0.006) and was lower at 12 months (p = 0.038). VAS was higher at 3 months and 6 months (all p < 0.05). TMH was lower at 12 months (all p < 0.05). U-VS was lower at 3 months (p = 0.006) and higher at 6 and 12 months (all p < 0.05). L-avGL was higher at 1 month (p = 0.001) and lower at 6 months (p = 0.013). L-VS was higher at 6 and 12 months (all p < 0.05). In the 0.02% group, at 3 months, the change in U-VS and L-VS were positively correlated with the change in the VAS (r = 0.542, p = 0.037; r = 0.614, p = 0.015). At 6 months, the change in L-VS was positively correlated with the change in OSDI (r = 0.610, p = 0.016). At 12 months, the change in U-VS was positively correlated with the change in TMH (r = 0.521, p = 0.003).Conclusion0.01% atropine had no significant impact. 0.02% atropine eye drops affected the lipid secretion of meibomian glands, tear meniscus height and subjective discomfort.https://www.frontiersin.org/articles/10.3389/fmed.2025.1585396/fulllow-concentration atropinemyopiachildrenocular surfacemeibomian gland bio-image analyzer |
| spellingShingle | Xueyan Li Yanying Zhu Haiyan Xie Yuexin Chen Yukun Liu Xiaochen Xu Jing Wang Changes in the ocular surface and meibomian glands following administration of 0.01 and 0.02% atropine Frontiers in Medicine low-concentration atropine myopia children ocular surface meibomian gland bio-image analyzer |
| title | Changes in the ocular surface and meibomian glands following administration of 0.01 and 0.02% atropine |
| title_full | Changes in the ocular surface and meibomian glands following administration of 0.01 and 0.02% atropine |
| title_fullStr | Changes in the ocular surface and meibomian glands following administration of 0.01 and 0.02% atropine |
| title_full_unstemmed | Changes in the ocular surface and meibomian glands following administration of 0.01 and 0.02% atropine |
| title_short | Changes in the ocular surface and meibomian glands following administration of 0.01 and 0.02% atropine |
| title_sort | changes in the ocular surface and meibomian glands following administration of 0 01 and 0 02 atropine |
| topic | low-concentration atropine myopia children ocular surface meibomian gland bio-image analyzer |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1585396/full |
| work_keys_str_mv | AT xueyanli changesintheocularsurfaceandmeibomianglandsfollowingadministrationof001and002atropine AT yanyingzhu changesintheocularsurfaceandmeibomianglandsfollowingadministrationof001and002atropine AT haiyanxie changesintheocularsurfaceandmeibomianglandsfollowingadministrationof001and002atropine AT yuexinchen changesintheocularsurfaceandmeibomianglandsfollowingadministrationof001and002atropine AT yukunliu changesintheocularsurfaceandmeibomianglandsfollowingadministrationof001and002atropine AT xiaochenxu changesintheocularsurfaceandmeibomianglandsfollowingadministrationof001and002atropine AT jingwang changesintheocularsurfaceandmeibomianglandsfollowingadministrationof001and002atropine |